Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Ex Vivo Perfusion of Discarded Donor Liver Segments for Comparative Therapeutic Investigations
Mohamed, Mohamed I. , Lu, Kang , Katta, Lavanya, Song, ZuoRui, Brown, Thomas D. , Orlando, Christopher , Nakhleh, Raouf E. , Kirkland, James L. , Kang, Lu, Brown, Thomas, Tchkonia, Tamar , Nguyen, Justin Hung

Mayo Clinic

Journal of the American College of Surgeons | April 17, 2023 | Volume: 236 | Issue: 5 | Pages: S118-S119

10.1097/01.xcs.0000933336.90051.69 Get It

Development of a portable abdominal normothermic regional perfusion (A-NRP) program in the United States
Croome, Kristopher P. , Brown, Thomas E. , Mabrey, Richard L., Sonnenwald, Sherry L., Burns, Justin M. , Mao, Shennen A. , Clendenon, Jacob N. , Nguyen, Justin H. , Perry, Dana K. , Maddox, Rebecca G., Clendenon, Jacob , Taner, Burcin , Croome, Kris P , Mao, Shennen A , Taner, C. Burcin

Mayo Clinic

Liver Transplantation | April 11, 2023 | Volume: 29 | Issue: 12 | Pages: 1282-1291

10.1097/lvt.0000000000000156 | PMID 37040930 Get It

In situ abdominal normothermic regional perfusion (A-NRP) has been used for liver transplantation (LT) with donation after circulatory death (DCD) liver grafts in Europe with excellent results; however, adoption of A-NRP in the United States has been lacking. The current report describes the implementation and results of a portable, self-reliant A-NRP program in the United States. Isolated abdominal in situ perfusion with an extracorporeal circuit was achieved through cannulation in the abdomen or femoral vessels and inflation of a supraceliac aortic balloon and cross-clamp. The Quantum Transport System by Spectrum was used. The decision to use livers for LT was made through an assessment of perfusate lactate (q15min). From May to November 2022, 14 A-NRP donation after circulatory death procurements were performed by our abdominal transplant team (N = 11 LT, N = 20 kidney transplants, and 1 kidney-pancreas transplant). The median A-NRP run time was 68 minutes. None of the LT recipients had post-reperfusion syndrome, nor were there any cases of primary nonfunction. All livers were functioning well at the time of maximal follow-up with zero cases of ischemic cholangiopathy. The current report describes the feasibility of a portable A-NRP program that can be used in the United States. Excellent short-term post-transplant results were achieved with both livers and kidneys procured from A-NRP.
Partial Inhibition of Complex I Restores Mitochondrial Morphology and Mitochondria-ER Communication in Hippocampus of APP/PS1 Mice
Panes, Jessica , Nguyen, Thi Kim Oanh , Gao, Huanyao , Christensen, Trace , Trushin, Sergey , Salisbury, Jeffrey L., Fuentealba, Jorge , Trushina, Eugenia , Stojakovic, Andrea , Gao, Huanyao , Trushina, Eugenia

Mayo Clinic

Cells | April 10, 2023 | Volume: 12 | Issue: 8 | Pages: 1111

10.3390/cells12081111 | PMID 37190020 Get It

Alzheimer’s disease (AD) has no cure. Earlier, we showed that partial inhibition of mitochondrial complex I (MCI) with the small molecule CP2 induces an adaptive stress response, activating multiple neuroprotective mechanisms. Chronic treatment reduced inflammation, Aβ and pTau accumulation, improved synaptic and mitochondrial functions, and blocked neurodegeneration in symptomatic APP/PS1 mice, a translational model of AD. Here, using serial block-face scanning electron microscopy (SBFSEM) and three-dimensional (3D) EM reconstructions combined with Western blot analysis and next-generation RNA sequencing, we demonstrate that CP2 treatment also restores mitochondrial morphology and mitochondria-endoplasmic reticulum (ER) communication, reducing ER and unfolded protein response (UPR) stress in the APP/PS1 mouse brain. Using 3D EM volume reconstructions, we show that in the hippocampus of APP/PS1 mice, dendritic mitochondria primarily exist as mitochondria-on-a-string (MOAS). Compared to other morphological phenotypes, MOAS have extensive interaction with the ER membranes, forming multiple mitochondria-ER contact sites (MERCS) known to facilitate abnormal lipid and calcium homeostasis, accumulation of Aβ and pTau, abnormal mitochondrial dynamics, and apoptosis. CP2 treatment reduced MOAS formation, consistent with improved energy homeostasis in the brain, with concomitant reductions in MERCS, ER/UPR stress, and improved lipid homeostasis. These data provide novel information on the MOAS-ER interaction in AD and additional support for the further development of partial MCI inhibitors as a disease-modifying strategy for AD.
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium
Tran, Benjamin V. , Moris, Dimitrios , Markovic, Daniela , Zaribafzadeh, Hamed , Lai, Quirino , Florman, Sander , Tabrizian, Parissa , Haydel, Brandy , Ruiz, Richard M., Klintmalm, Göran B. , Lee, David D. , Verna, Elizabeth C. , Halazun, Karim J. , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Lerut, Jan , Nguyen, Mindie H. , Viveiros, André , Schaefer, Benedikt , Hoppe‐Lotichius, Maria , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, R. Mark , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Busuttil, Ronald W. , Barbas, Andrew S. , Lai, Quirino , Florman, Sander S , Tabrizian, Parissa , Haydel, Brandy , Klintmalm, Goran , Lee, David D , Taner, Burcin , Hoteit, Maarouf , Levine, Matthew H , Cillo, Umberto , Verna, Elizabeth C , Halazun, Karim J , Tevar, Amit D , Humar, Abhinav , Chapman, William C , Vachharajani, Neeta , Ciccarelli, Olga , Nguyen, Mindie H , Melcher, Marc L , Viveiros, Andre , Schaefer, Benedikt , Hoppe-Lotichius, Maria , Mittler, Jens , Markmann, James F , Rossi, Massimo , Mobley, Constance , Ghobrial, Mark , Schnickel, Gabriel T , Sudan, Debra L , Hong, Johnny C , Rana, Abbas , Jones, Christopher M , Busuttil, Ronald W , Barbas, Andrew S , Agopian, Vatche G , Moris, Dimitrios , Henao, Ricardo , Ruiz, Richard , Taner, C. Burcin , Vitale, Alessandro , Melcher, Marc L. , Carney, Carol A., Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | April 7, 2023 | Volume: 29 | Issue: 7 | Pages: 683-697

10.1097/lvt.0000000000000145 | PMID 37029083 Get It

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT HCC recurrence risk remains an important need. Clinico-radiologic and pathologic data of 4981 patients with HCC undergoing LT from the US Multicenter HCC Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine and Gray competing risk analysis and machine learning algorithms (Random Survival Forest and Classification and Regression Tree models) identified variables to model HCC recurrence. RELAPSE was externally validated in 1160 HCC LT recipients from the European Hepatocellular Cancer Liver Transplant study group. Of 4981 UMHTC patients with HCC undergoing LT, 71.9% were within Milan criteria, 16.1% were initially beyond Milan criteria with 9.4% downstaged before LT, and 12.0% had incidental HCC on explant pathology. Overall and recurrence-free survival at 1, 3, and 5 years was 89.7%, 78.6%, and 69.8% and 86.8%, 74.9%, and 66.7%, respectively, with a 5-year incidence of HCC recurrence of 12.5% (median 16 months) and non-HCC mortality of 20.8%. A multivariable model identified maximum alpha-fetoprotein (HR = 1.35 per-log SD, 95% CI,1.22–1.50, p < 0.001), neutrophil-lymphocyte ratio (HR = 1.16 per-log SD, 95% CI,1.04–1.28, p < 0.006), pathologic maximum tumor diameter (HR = 1.53 per-log SD, 95% CI, 1.35–1.73, p < 0.001), microvascular (HR = 2.37, 95%–CI, 1.87–2.99, p < 0.001) and macrovascular (HR = 3.38, 95% CI, 2.41–4.75, p < 0.001) invasion, and tumor differentiation (moderate HR = 1.75, 95% CI, 1.29–2.37, p < 0.001; poor HR = 2.62, 95% CI, 1.54–3.32, p < 0.001) as independent variables predicting post-LT HCC recurrence (C-statistic = 0.78). Machine learning algorithms incorporating additional covariates improved prediction of recurrence (Random Survival Forest C-statistic = 0.81). Despite significant differences in European Hepatocellular Cancer Liver Transplant recipient radiologic, treatment, and pathologic characteristics, external validation of RELAPSE demonstrated consistent 2- and 5-year recurrence risk discrimination (AUCs 0.77 and 0.75, respectively). We developed and externally validated a RELAPSE score that accurately discriminates post-LT HCC recurrence risk and may allow for individualized post-LT surveillance, immunosuppression modification, and selection of high-risk patients for adjuvant therapies.
Expectations Regarding Gastein Healing Gallery Treatment and Their Connection to Health-Related Quality of Life
Toussaint, Loren , Huynh, Kien, Kohls, Niko , Sirois, Fuschia M. , Alberts, Hannah, Hanshans, Christian , Nguyen, Quang Anh , Offenbäecher, Martin, Sirois, Fuschia , Hanshans, Christian , Toussaint, Loren L , Hirsch, Jameson K. , Zee‐Neuen, Antje van der , Offenbächer, Martin

Mayo Clinic

International Journal of Environmental Research and Public Health | April 6, 2023 | Volume: 20 | Issue: 7 | Pages: 5426

10.3390/ijerph20075426 | PMID 37048040 Get It

The present study examines connections between patient expectations and health-related quality of life. We explore a key distinction between expectations about general health and expectations for functional improvement. Patients were 1444 individuals with multiple conditions experiencing chronic pain who were seeking treatment at the Gastein Healing Gallery in Böckstein, near Bad Gastein, Austria. In addition to measures of expectations, patients completed measures of pain, mental and physical health, life satisfaction, fatigue, and sleep problems. Structural equation models were used to fit a latent variable model where both expectation variables were used to predict health-related quality of life. Results showed that expectations regarding potential functional improvement resulting from treatments at the Gastein Healing Gallery were associated with improved health-related quality of life. Expectations about general health improvements related to treatment were not associated with health-related quality of life. To facilitate optimal healing, clinicians may decide to emphasize expectations about functional recovery when discussing treatment methods similar to those offered at the Gastein Healing Gallery, and in so doing, health-related quality of life may benefit.
Abstract 4082: Impact of immunosuppressive monocytes on CART19 cell effector functions and outcomes
Yun, Kun , Huynh, Truc , Manriquez-Roman, Claudia, Sirpilla, Olivia , Stewart, Carli M. , Girsch, James H. , Ogbodo, Ekene J. , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Mattie, Mike , Nguyen-Mau, Sao-Mai, Sakemura, Reona , Cox, Michelle J. , Stewart, Carli , Can, İsmail , Kimball, Brooke , Hefazi, Mehrdad , Siegler, Elizabeth L. , Filosto, Simone , Kenderian, Saad S.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 4082-4082

10.1158/1538-7445.am2023-4082 Get It

Abstract CD19 directed chimeric antigen receptor T (CART19) cell therapy has resulted in remarkable outcomes in B cell malignancies and was FDA approved in multiple indications. However, durable remissions are limited to 40% of treated patients. Inhibitory myeloid cells in tumor microenvironment have been found to suppress T cell expansion and contribute to failure of CART19 cell therapy. In this study, we aimed to unravel the interactions between monocytes, CART19 cells and tumor cells to understand how monocytes-CART19 cell interactions impact CART19 cell effector functions and clinical outcomes. Two sets of experiments were conducted, 1) use of healthy CART19 cells, CD19+ tumor cells, and healthy monocytes; 2) use of brexu-cel products from ZUMA-2 clinical trial treating mantle cell lymphoma (MCL), patient-matched monocytes and circulating MCL tumor cells (n = 11; 6 durable responders, 2 relapsed after initial response and 3 non-responders). CD28 costimulated CART19 (CART19-28ζ) cells generated in the lab from healthy donors were co-cultured with donor freshly isolated monocytes in the presence of Jeko-1 cells (a CD19+ MCL cell line). CART19 antigen specific proliferation was not inhibited by freshly isolated monocytes. When monocytes were co-cultured with CART19 and tumor cells, higher levels of eotaxin, GRO, MCP-3 and IL-7 were detected. When CART19 cells were co-cultured with the CD19+ JeKo-1 cells in the presence of ex vivo M2 polarized macrophages, CART19 antigen specific proliferation was inhibited (p=0.0045). Transwell experiments demonstrate that M2-induced CART19 inhibition is not contact dependent. Cytokine profile analysis indicated increased level of IL-1ra, IP-10 and MCP-1 and decreased level of IL-17A, sCD40L, IL-9 and MIP-1α when M2 macrophages were co-cultured with CART19 and tumor cells compared to co-cultures of tumor cells and CART19. Then we conducted ex vivo co-cultures of brexu-cel products, autologous monocytes and circulating MCL tumor cells from MCL patients (ZUMA-2) collected prior to CART19 cell infusion. Here we observed trends of elevation of IL-13 and IL-5 and reduction of GRO, MCP-3, MIP-1β and IL-8 in non-responders, compared to responders (durable responses or relapsed patients). Our results support that monocyte- and macrophage-dependent cytokine release could modulate CART19 effector and trafficking functions, and thus CART19 clinical outcomes. This warrants further investigation around strategies to improve durable responses to CART cell therapy. Citation Format: Kun Yun, Reona Leo Sakemura, Michelle J. Cox, Truc Huynh, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, James H. Girsch, Ekene J. Ogbodo, Ismail Can, Brooke Kimball, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Elizabeth L. Siegler, Mike Mattie, Sao-Mai Nguyen-Mau, Simone Filosto, Saad S. Kenderian. Impact of immunosuppressive monocytes on CART19 cell effector functions and outcomes. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4082.
Abstract 624: The role of draining lymph nodes in the post-transplant recurrence of liver cancer: Examining immune response using spatial proteomics
Hickman, Peyton G. , Thompson, Aubrey, Nguyen, Justin H.

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 624-624

10.1158/1538-7445.am2023-624 Get It

Abstract Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CCA) are the predominant forms of liver cancer, with a devastating combined incidence of 40,000 cases per year in the United States. Despite many differences between the cancers, liver transplant has found great success in treating both over traditional methods. However, up to 35% of patients’ cancer still recur within five years. Given the risk and resource intensiveness of this treatment, it is critical to identify factors that influence recurrence in these cancers. Previous studies have found the micro-environments of HCC tumors tend to be immune-active while those of CCA tumors tend to be immunosuppressive. Increased immune activity at the tumor level is associated with better patient outcomes, but the role and impact of the regional immune response in liver cancer is not well understood. Liver draining lymph node tissue was collected from patients undergoing orthotopic liver transplant (OLT) for HCC, CCA, or other reasons (control). Nanostring GeoMx Digital Spatial Profiler (DSP) was used to measure immune marker levelsWe found increased immune activity in the LNs of patients with HCC compared to CCA, showing significantly higher levels of lymphocytes and immune activity markers, matching previous tumor microenvironment findings. Additionally, comparing recurrent and non-recurrent HCC or CCA samples, we see generally increased immune activity in non-recurrent lymph nodes, also identifying specific immune markers in both cancer types that correlate with cancer recurrence or non-recurrence. These also reveal patterns of activity specific to both cancer type and recurrence status. Overall, this study provides novel insights into the regional immune response in liver cancers and identifies candidate proteins to serve as predictors of recurrence in liver cancer. We suggest CD163, CD66b, CD8, and CD56 as markers to predict post-OLT HCC recurrence and CD163, CD66b, ID01, and OX40L as candidate markers to predict post-OLT CCA recurrence using LN samples. Further spatial analysis of this data may further characterize immune activity in these lymph nodes, and future studies focusing on identified differences in immune activity may reveal factors affecting liver cancer aggressiveness and recurrence. Citation Format: Peyton Hickman, Aubrey E. Thompson, Justin Nguyen. The role of draining lymph nodes in the post-transplant recurrence of liver cancer: Examining immune response using spatial proteomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 624.
CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)
Larson, Joseph J. , McCue, Shaylene , Fernández-Zapico, Martín E. , Revzin, Alexander , Fonkoua, Lionel Aurelien Kankeu , Flickinger, Lynn M. , Jatoi, Aminah , Tran, Nguyen H. , Ou, Fang‐Shu , Mahipal, Amit , Graham, Rondell P. , Cleary, Sean P. , Bekaii‐Saab, Tanios , Borad, Mitesh J. , McWilliams, Robert R. , Wee, Wen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: CLO23-030

10.6004/jnccn.2022.7121 Get It

Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting
Sharma, Pravesh , Mathews, Doug B, Nguyen, Quang Anh , Rossmann, Gillian, A Patten, Christi, Sharma, Pravesh , Patten, Christi A. , Hammond, Christopher J.

Mayo Clinic

Clinical Medicine Insights: Pediatrics | March 25, 2023 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/11795565231162297 | PMID 36993933 Get It

Cannabis vaping has emerged as a predominant mode of cannabis use among United States (US) adolescents and young adults (AYA) primarily due to the popularity of modifiable designs of vaping devices coupled with changes in cannabis policies and increased availability of cannabinoid products. New methods for cannabis vaping by e-liquid/oil vaping, dry plant vaping, and cannabis concentrate vaping (ie, dabbing) have had high uptake among American youth with unclear long-term health implications. Issues with contamination, mislabeling, and expansion of the vaped cannabis market to include not only delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD) but also delta-9-THC analogs (eg, delta-8 and delta-10) sold as hemp-derived “legal highs” further complicated this healthcare space. Recent research suggests that cannabis/THC vaping carries distinct and overlapping risks when compared to cannabis smoking and may be associated with greater risk for acute lung injuries, seizures, and acute psychiatric symptoms. Primary care clinicians providing care for AYA are in an ideal position to identify cannabis misuse and intervene early to address cannabis vaping. To improve public health outcomes, a need exists for pediatric clinicians to be educated about different ways/methods that youth are vaping cannabinoid products and associated risks related to cannabinoid vaping. Further, pediatric clinicians need to be trained how to effectively screen for and discuss cannabis vaping with their youth patients. In the current article, we present a clinically focused review of cannabis vaping among young people with 3 main aims to: (1) identify and describe the cannabis vaping products commonly used by American youth; (2) review the health correlates of youth cannabis vaping; and (3) discuss clinical considerations related to identifying and treating youth who vape cannabis.
International Liver Transplantation Society/Society for Advancement of Transplant Anesthesia Consensus Statement on Essential Attributes of a Liver Transplant Anesthesiologist
Bhangui, Pooja , Pustavoitau, Aliaksei , Sabaté, A. , Wagener, Gebhard , Wray, Christopher , Pan, Terry Ling Te , Nguyen, Christine , Bezinover, Dmitri , Biancofiore, Gíanni , Blasi, Annabel , Chadha, Ryan , Saner, Fuat Hakan , Zerillo, Jeron

Mayo Clinic

Transplantation | March 22, 2023 | Volume: 107 | Issue: 7 | Pages: 1427-1433

10.1097/tp.0000000000004583 | PMID 36944597 Get It

Background. We sought to establish consensus on the essential skills, knowledge, and attributes that a liver transplant (LT) anesthesiologist should possess in a bid to help guide the further training process. Methods. Consensus was achieved via a modified Delphi methodology, surveying 15 identified international experts in the fields of LT anesthesia and critical care. Results. Key competencies were identified in preoperative management and optimization of a potential LT recipient; intraoperative management, including hemodynamic monitoring; coagulation and potential crisis management; and postoperative intensive and enhanced recovery care. Conclusions. This article provides an essential guide to competency-based training of an LT anesthesiologist.